Medinno Raises More Than RMB 200 Million to Advance Topical Drug for Diabetic Foot Ulcers
Medinno has raised more than RMB 200 million in a Series A financing led by Sunshine Ronghui Capital, giving the company fresh funding to develop MDI-1228, a topical drug candidate for diabetic foot ulcers and other conditions. The proceeds will support…
GSK Returns to Chimagen for Multiple Myeloma T-Cell Engager in Deal Worth Up to $750 Million
GSK is expanding its relationship with China’s Chimagen Biosciences, agreeing to acquire global rights to an experimental trispecific T-cell engager for multiple myeloma in a transaction worth up to $750 million. The agreement, announced September 15,…
GSK and Hansoh’s Ris-Rez Cuts Risk of Death by 54% in Phase 3 Small-Cell Lung Cancer Trial
GSK and Hansoh Pharma’s B7-H3-directed antibody-drug conjugate risvutatug rezetecan delivered a striking survival benefit in relapsed small-cell lung cancer, potentially setting a new benchmark for a disease in which treatment progress has historically…
iRegene’s NouvSight001 Cleared for Retinitis Pigmentosa Trials in China and U.S.
iRegene Therapeutics has secured regulatory clearance in both China and the United States to move NouvSight001, its off-the-shelf photoreceptor cell therapy, into clinical development for retinitis pigmentosa (RP), giving the company another opportunity…
CTTQ’s HER2 Bispecific ADC TQB2102 Hits Phase 3 Endpoints in HER2-Low Breast Cancer, Setting Up China Filing
Chia Tai Tianqing Pharmaceutical Group (CTTQ), a core subsidiary of Sino Biopharmaceutical, has reported a major late-stage clinical win for TQB2102 (rolditamig deuderuxtecan), its internally developed HER2 bispecific antibody-drug conjugate (ADC). The…
ApicHope’s AR882 Beats Febuxostat in China Phase 3 Gout Trial, Meeting Primary Endpoint
China’s ApicHope Pharmaceutical Group has reported positive topline results from a Phase 3 clinical trial of AR882 (pozdeutinurad), its next-generation URAT1 inhibitor for gout, showing statistically significant superiority over febuxostat in lowering…
China NMPA Clears Five Novel Drugs and Two New Indications in September Approval Wave
China’s National Medical Products Administration (NMPA) delivered another busy round of regulatory decisions in early September 2026, clearing a group of innovative therapies spanning oncology, infectious disease, cardiovascular medicine, hematology and…
2026 China Healthcare Decision-Makers Conference (CHDC)
Every step forward in corporate competitiveness begins with the judgment and leadership of decision-makers. From target selection and technology platform choices to product portfolio decisions, clinical development strategies, BD transactions, market…
ALLYRNA Raises Over RMB 100 Million to Advance RNA Epigenetics-Based Cancer Drug Pipeline
Shanghai-based ALLYRNA has raised more than RMB 100 million in Seed+ financing to advance a new generation of small-molecule cancer therapies derived from RNA epigenetics, including potential radiotherapy and immunotherapy sensitizers for…
2026 H2 AbbVie China Partnering Day
In 2026, cross-border licensing transactions for innovative drugs in China continued to heat up, and multinational pharmaceutical companies accelerated their efforts to expand their local innovation in China. Recently, AbbVie, a global research-based…